3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
33
OTHER
30
NETWORK
4
OTHER_GOV
2
NIH
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Sleep Initiation and Maintenance Disorders
1
Fatigue
1
Depression
1
Adenocarcinoma
1
Interventions
Capecitabine
9
Bevacizumab
8
tislelizumab
7
Oxaliplatin
7
Drug Therapy
7
pembrolizumab
6
Surgical Procedures, Operative
6
Cisplatin
6
Standard of Care
5
Radiotherapy
5
Laparoscopy
5
Fluorouracil
5
Docetaxel
5
Carboplatin
5
toripalimab
4
Radiosurgery
4
Leucovorin
4
Exercise
4
Epirubicin
4
Cyclophosphamide
4
pertuzumab
3
durvalumab
3
dalpiciclib
3
atezolizumab
3
anlotinib
3
Saline Solution
3
Rituximab
3
Radiation
3
Prednisone
3
Population Groups
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER_GOV
×
darolutamide
×
1 year
×
Clear all
NCT07617272
2026-06-01
PARIS-BIO
Region Stockholm
Phase 2
Recruiting
100 enrolled
NCT07181122
2026-04-28
PRO-MIND
Ankara Etlik City Hospital
Recruiting
102 enrolled